Seiji Niho
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (9)
IgG4‐related disease (IgG4‐RD) is a fibroinflammatory disease characterised by elevated serum IgG4 levels and marked infiltration of IgG4‐positive plasma cells. Here, we present the case of a 49‐year‐old man who presented with dysphagia and hoarseness caused by an anterior mediastinal mass. As the fluorodeoxyglucose positron emission tomography (FDG‐PET) SUVmax was 6.68 (early and delayed), malignancy was initially suspected. Serum IgG4 levels were slightly elevated at 148 mg/dL. Surgical biopsy revealed dense lymphoplasmacytic infiltration with storiform fibrosis and numerous IgG4‐positive plasma cells, fulfilling the diagnostic criteria for IgG4‐RD. Treatment with high‐dose prednisolone (60 mg/day) rapidly resolved symptoms and markedly reduced the mass within 6 months. This case highlights the importance of considering IgG4‐RD in the differential diagnosis of mediastinal tumours, even when FDG‐PET shows abnormal accumulation and serum IgG4 levels are not particularly high.
Year:
2026
Objective Abraxane ® intravenous infusion (albumin-bound paclitaxel nanoparticles; Abraxane ® or paclitaxel nanoparticles) is a lyophilized cake formulation containing paclitaxel and human serum albumin in nanoparticulate form. Before use, it must be uniformly dispersed in saline. However, this reconstitution process often leads to foaming, necessitating careful handling and prolonging preparation time. This study aimed to investigate shaking conditions for rapid, uniform paclitaxel nanoparticle dispersion while minimizing foam formation. Additionally, we evaluated whether shaking affects nanoparticle size. Methods After adding 20 mL of saline to a vial containing 100 mg of lyophilized cake, the vial was placed either vertically or horizontally on a shaker. Two shaking types were examined: linear reciprocal and orbital shaking. We varied shaking intensity and recorded the dispersion time and foam formation. Particle size was analyzed under the following three conditions: (1) control, (2) minimal dispersion time without foaming, and (3) the condition causing the most severe foaming. Results When the vial was placed horizontally and subjected to orbital shaking at 100 rpm, uniform dispersion was achieved within 6.25 min without foaming. This was approximately one-third the time required under control conditions. Further, when particle size was measured under different shaking intensities in the horizontal setup, no significant change in nanoparticle size was observed regardless of shaking strength or time after preparation. Conclusion In the reconstitution of Abraxane ® , the optimal shaking condition identified in this study was demonstrated to not only preserve nanoparticle integrity but also reduce the time and effort required for healthcare professionals.
Year:
2026
Purpose: This study was performed to confirm the superiority in overall survival (OS) of EGFR tyrosine kinase inhibitor (TKI gefitinib or osimertinib) monotherapy versus EGFR TKI with intercalation of cisplatin plus pemetrexed as the first-line treatment for patients with advanced non-squamous non–small cell lung cancer (NSqNSCLC) harboring EGFR mutation. Patients and Methods: This was an open-label, multicenter, randomized phase III study. Patients with chemotherapy-naïve advanced or recurrent NSqNSCLC harboring EGFR mutation (exon 19 deletion or exon 21 L858R point mutation) were randomly assigned (1:1) to EGFR-TKI monotherapy or the EGFR TKI plus intercalated chemotherapy group. The primary endpoint was OS, and the secondary endpoints included progression-free survival (PFS). Results: From December 2015 to October 2020, 501 patients were randomized. The EGFR TKI was changed from gefitinib to osimertinib in October 2018 (gefitinib cohort: n = 308 and osimertinib cohort: n = 193). There was no survival advantage in the EGFR TKI plus intercalated chemotherapy group; the median survival time of both groups was 48.0 months (HR, 0.985; 91.4% confidence interval, 0.796–1.219; one-sided P = 0.4496). The median PFS time was 12.0 months in the EGFR-TKI monotherapy group and 18.0 months in the EGFR TKI plus intercalated chemotherapy group (HR, 0.762; 95% confidence interval, 0.628–0.925; one-sided P = 0.003). The OS and PFS trends in both gefitinib and osimertinib cohorts were identical to those in the entire population. Conclusions: The intercalation of cisplatin plus pemetrexed after the response to EGFR TKI improved PFS but not OS compared with EGFR TKI monotherapy as the first-line treatment for patients with advanced NSqNSCLC harboring EGFR mutation.
Year:
2025
Supplementary Figure S3. Subgroup analyses of overall survival. (A) Gefitinib cohort. (B) Osimertinib cohort. Abbreviations: CI, confidence interval; EGFR, epidermal growth factor receptor; Ex19del, EGFR exon 19 deletion; L858R, EGFR exon 21 L858 point mutation; ECOG, Eastern Clinical Oncology group; PS, performance status; EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor; CNS, central nervous system.
Year:
2025
Kaplan–Meier analysis of OS. A, ITT population. The 1-, 2-, 3-, 4-, and 5-year survival rates were 92.8%, 80.4%, 63.5%, 49.6%, and 36.9% in the control group and 94.4%, 81.7%, 69.9%, 49.9%, and 35.3% in the experimental group, respectively. B, Gefitinib cohort. The 1-, 2-, 3-, 4-, and 5-year survival rates were 91.5%, 78.4%, 59.5%, 46.3%, and 34.4% in the control group and 92.2%, 77.7%, 66.4%, 46.5%, and 32.9% in the experimental group, respectively. C, Osimertinib cohort. The 1-, 2-, and 3-year survival rates were 94.8%, 83.4%, and 69.8% in the control group and 97.9%, 88.3%, and 76.0% in the experimental group, respectively. D, Subgroup analysis of OS. ECOG, Eastern Clinical Oncology Group; Ex19del, EGFR exon 19 deletion; L858R, EGFR exon 21 L858 point mutation; NE; not estimable; PS, performance status.
Year:
2025
Kaplan–Meier analysis of PFS. A, ITT population. The 1-, 2-, 3-, 4-, and 5-year PFS rates were 49.2%, 26.0%, 18.0%, 12.9%, and 7.8% in the control group and 67.0%, 39.8%, 24.1%, 11.9%, and 9.5% in the experimental group, respectively. B, Gefitinib cohort. The 1-, 2-, 3-, 4-, and 5-year PFS rates were 37.3%, 13.7%, 8.5%, 6.5%, and 4.0% in the control group and 59.5%, 32.7%, 15.7%, 7.2%, and 5.7% in the experimental group, respectively. C, Osimertinib cohort. The 1-, 2-, and 3-year PFS rates were 68.0%, 45.3%, and 32.2% in the control group and 79.0%, 51.4%, and 39.6% in the experimental group, respectively. D, Subgroup analysis of PFS. ECOG, Eastern Clinical Oncology Group; Ex19del, EGFR exon 19 deletion; L858R, EGFR exon 21 L858 point mutation; PS, performance status.
Year:
2025
Supplementary Figure S4. Subgroup analyses of progression-free survival. (A) Gefitinib cohort. (B) Osimertinib cohort. Abbreviations: CI, confidence interval; EGFR, epidermal growth factor receptor; Ex19del, EGFR exon 19 deletion; L858R, EGFR exon 21 L858 point mutation; ECOG, Eastern Clinical Oncology group; PS, performance status; EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor; CNS, central nervous system.
Year:
2025
Supplementary Figure S2. Study design of JCOG1404/WJOG8214L. Abbreviations: NSCLC, non-small cell lung cancer; EGFR; epidermal growth factor receptor; Exon 19 DEL, EGFR exon 19 deletion; Exon 21 L858R, EGFR exon 21 L858 point mutation; ECOG, Eastern Clinical Oncology Group; PS, performance status; CNS, central nervous system; EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor; PD, progressive disease.
Year:
2025
Background We conducted a phase II study of carboplatin plus nab‐paclitaxel for the treatment of small cell lung cancer (SCLC) after the failure of a prior standard chemotherapy containing platinum, etoposide, irinotecan, and amrubicin if indicated. Patients with interstitial pneumonia complications were included in the study. Methods Patients received 100 mg/m 2 of nab‐paclitaxel weekly (on days 1, 8, and 15) and an AUC 5 of carboplatin on day 1. The study treatment was repeated every 3 weeks until disease progression or the appearance of unacceptable toxicities. The primary endpoint was the objective response rate. Results A total of 21 patients were enrolled, all of whom were eligible for inclusion in the analysis. Twelve patients had pre‐existing interstitial pneumonia. The overall response rate was 19.0% (90% confidence interval [CI]: 6.8%–38.4%). The lower limit of the 90% CI for the response rate did not exceed the prespecified threshold value of 10%. Among the 12 patients with pre‐existing interstitial pneumonia, the response rate was 25%. The median progression‐free survival time was 2.5 months (95% CI: 1.5–3.4 months), and the median survival time was 5.1 months (95% CI: 2.1–8.1 months). Two patients developed interstitial lung disease; both of these patients had pre‐existing interstitial pneumonia. One of the patients died from interstitial lung disease. Conclusion Combination chemotherapy with carboplatin plus nab‐paclitaxel for recurrent SCLC had a modest activity, although the primary study endpoint was not met. Further investigation of this regimen for patients with recurrent SCLC and interstitial pneumonia is warranted.
Year:
2022
Collaborators (8)
Shintaro Kanda
Professor
Shinshu University
Hirokazu Taniguchi
Senior Assistant Professor
Nagasaki University Hospital
Takayasu Kurata
-
Yutaka Fujiwara
Head
Aichi Cancer Center
Shogo Nomura
Associate Professor
University of Tokyo
Eiji Iwama
Kyushu University
Kazuyuki Ishida
Dokkyo Medical University
Koichi Azuma
Kurume University School of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.